Zydus Cadila gets DCGI nod to initiate Phase-3 clinical trials for COVID-19 vaccine

By: |
January 3, 2021 4:48 PM

ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, DCGI added

Zyndus Cadilla, covid vaccine in india, covid-19 vaccination, DCGI approval phase III trial sof Zyndus Cadilla covid vaccineThe phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers . (Site Image)

Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D. The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement.ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, it added.

The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said. The trial has reviewed by an independent data safety monitoring board (DSMB) and reports were submitted to the Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

“We are reaching a critical milestone in our vaccine development programme and towards our goal of helping people fight the pandemic with an indigenously discovered, safe and efficacious vaccine,” Zydus Group Chairman Pankaj R Patel said.

The launch of the Phase 3 trial will determine the efficacy of the company’s vaccine in preventing COVID-19, which continues to pose a major threat world over, he added.

The Drug Controller General of India (DCGI) on Sunday granted emergency approval to Serum Institute and Bharat Biotech for their respective vaccines.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1UK university scientists finalise nasal spray that blocks out COVID-19: Report
2Vaccinated people may still transmit COVID-19, warns England’s chief medic
3Pakistan approves emergency use of Russia’s Sputnik V COVID-19 vaccine